Stockscreener 앱 받기
1.16
1.75%
0.02
시간 외 거래:
1.16
전일 마감가:
$1.14
열려 있는:
$1.15
하루 거래량:
2.28M
Relative Volume:
0.44
시가총액:
$223.88M
수익:
$1.57M
순이익/손실:
$-39.34M
주가수익비율:
-4.8576
EPS:
-0.2388
순현금흐름:
$-106.40M
1주 성능:
+4.50%
1개월 성능:
+14.85%
6개월 성능:
-21.09%
1년 성능:
-58.12%
1일 변동 폭
$1.14
$1.22
1주일 범위
$1.095
$1.31
52주 변동 폭
$0.88
$3.36
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.16 | 220.02M | 1.57M | -39.34M | -106.40M | -0.2388 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Aug Macro: What are Humacyte Inc Equity Warrants technical support levels2026 Risk Factors & Weekly High Momentum Picks - baoquankhu1.vn
Humacyte at Barclays Conference: Strategic Insights and Future Plans By Investing.com - Investing.com Canada
Risk Analysis: Will Humacyte Inc benefit from rising consumer demandQuarterly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Institution Moves: Does Humacyte Inc have a sustainable dividend2026 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Humacyte, Inc. (HUMA) Is Viewed Favorably by Analysts: Does This Hold Up? - Bitget
HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Stocktwits
Humacyte at TD Cowen Conference: Strategic Advances in Vascular Care By Investing.com - Investing.com Canada
Bioengineered tissue firm Humacyte lines up back-to-back March investor talks - Stock Titan
US Stocks Recap: Can Humacyte Inc sustain its profitabilityTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte To Participate in Upcoming Investor Conferences - Bitget
Levels Update: What is the long term forecast for Humacyte Inc stock2025 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 527% Upside with Innovative Biotech Solutions - DirectorsTalk Interviews
HUMA Should I Buy - Intellectia AI
HUMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP - MarketBeat
Will Humacyte Inc. Equity Warrant face regulatory challengesWeekly Gains Report & Free Community Supported Trade Ideas - mfd.ru
What’s the fair value of Humacyte Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - mfd.ru
Why Humacyte Inc. stock is favored by top institutions2025 Retail Activity & Fast Gaining Stock Strategy Reports - mfd.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unpacking A 570% Potential Upside - DirectorsTalk Interviews
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Insider Trends: Should I invest in Humacyte Inc Equity Warrant before earningsJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting - Bitget
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - The Manila Times
Hedge Fund Moves: Can Humacyte Inc deliver consistent EPS growthTrade Ideas & Accurate Trade Setup Notifications - baoquankhu1.vn
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential - Yahoo Finance
Humacyte Shares Surge on US Defense Funding News - StocksToTrade
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte promotes critical role of vascular health in February - Traders Union
Is Humacyte Inc. backed by strong institutional buyingWeekly Trade Recap & Proven Capital Preservation Methods - mfd.ru
Surprises Report: Whats the fair value of Humacyte Inc stock2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Chart Watch: Why Humacyte Inc. Equity Warrant stock remains on buy listsRate Hike & Reliable Breakout Forecasts - mfd.ru
Can Humacyte Inc. sustain earnings growthQuarterly Trade Review & High Conviction Investment Ideas - mfd.ru
Does Humacyte Inc. Equity Warrant stock benefit from AI growth2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Is Humacyte Inc. a speculative investmentJuly 2025 Intraday Action & Stepwise Trade Execution Plans - mfd.ru
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential - Sahm
HUMA stock just shot up 12% today – here’s everything to know about the DOD funding fueling the surge - MSN
Humacyte, Inc. (HUMA) - DirectorsTalk Interviews
Aug Levels: Should I invest in Humacyte Inc Equity Warrant before earnings - baoquankhu1.vn
Sell Signal: Can Humacyte Inc deliver consistent EPS growthJuly 2025 Analyst Calls & Weekly High Return Opportunities - baoquankhu1.vn
Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use - simplywall.st
Bond Watch: Can Humacyte Inc deliver consistent EPS growthWeekly Investment Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) falls more steeply than broader market: What investors need to know - MSN
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
HUMA Stock Soars Amid Strategic Business Moves and Financial Outlook - StocksToTrade
HUMA Stock Shows Volatility Amid Speculation and Economic Factors - timothysykes.com
Why Humacyte (HUMA) Is Up 19.6% After New DoD Funding For Biologic Vascular Repair - Yahoo Finance
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist (NASDAQ:HUMA) - Seeking Alpha
Humacyte rises on Department of Defense funding for lab-made blood vessels - TradingView
Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):